Updated Results of DESTINY-Breast03 T-DXd vs T-DM1 for Previously Treated Patients With HER2-Positive Metastatic Breast Cancer – The ASCO Post

By Matthew Stenger Posted: 1/26/2023 10:52:00 AM Last Updated: 1/26/2023 11:58:20 AM As reported in The Lancet by Sara A. Hurvitz, MD, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs…

Read the full article here

Related Articles